Why Tirzepatide Continues to Outpace Semaglutide in India
Three months after the patent on semaglutide (the active ingredient in Novo Nordisk’s diabetes and weight-loss drugs like…
Why the weight-loss drugs battle will intensify in 2026, explained in 5 charts
Novo executives project that oral pills could capture more than a third of the total obesity drug market…
2 No-Brainer Healthcare Stocks to Buy Now
Pfizer’s acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach…